Morgan Stanley upgraded NeuroPace to Equal Weight from Underweight with a price target of $6, up from $5. The firm says its prior Underweight thesis was based on persistent pandemic headwinds that have largely played out. NeuroPace’s patient funnel and implant volumes have stabilized and or improved, and it has demonstrated cost discipline, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NPCE:
- NeuroPace to Participate in Upcoming Investor Conferences
- NeuroPace raises FY23 revenue view to $59M-$61M from $52M-$54M
- NeuroPace reports Q2 EPS (36c), consensus (46c)
- NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
- NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market